Table 5.

Cox regression model with the estimated hazard ratios of having evidence of disease activity on Ocrelizumab for different covariates.

	B	SE	Wald	p	HR	95.0% CI for HR
						Lower	Upper
Gender	−.459	.534	.739	.390	.632	.222	1.800
Age	−.016	.030	.292	.589	.984	.928	1.043
Duration of illness	.035	.044	.636	.425	1.036	.950	1.130
Number of relapses during the two years before starting Ocrelizumab	.894	.447	3.995	.046	2.445	1.018	5.874

Abbreviations. CI, confidence interval; HR, hazard ratio.